The use of plant extracts and bacteriophages as an alternative therapy approach in combating bacterial infections: the study of lytic phages andStevia rebaudiana
preprint
OA: closed
CC-BY-NC-ND-4.0
Abstract
Introduction In the light of the problem of antibiotic-resistance, the use of alternative combined therapies in combating bacterial-related issues has gained popularity. Therefore, using up-to-date laboratory techniques, possible interactions of lytic bacteriophages (MS2, T4 and Phi6), acetone and methanol S. rebaudiana extracts (SRa and SRm) in the bacterial environment have been examined. Material and Methods Using a microdilution method, phages-extracts coincubation assay, static interactions synographies and dynamic growth profile experiments in a bioreactor, it was found that the interactions in a static environment differ from interactions in a dynamic environment. Results Dynamic conditions alter the influence of extracts in a concentration-dependent manner. The effects of the SRa and SRm extracts on bacterial growth in a dynamic environment depend on the species of the phage and bacterial host. The greatest differences were observed for E. coli strains and their phages, whereas P. syringae and Phi6 phage reacted very similar to both extracts. The differences also emerged for single extracts within E. coli strains and their phages. Conclusions Every extract type should be tested on a case-by-case basis and experiments outcomes should not be generalized before gathering data. Moreover, many varied experiments should be performed, especially when examining such multifactorial mixtures. Tested mixtures could be potentially used in multi-drug resistant bacterial infections treatments.
My notes (saved in your browser only)
Citation neighborhood (no data yet)
We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.
References (30)
- doi:10.3389/fmicb.2017.00981 via crossref
- doi:10.3390/antibiotics9080480 via crossref
- doi:10.1111/j.1439-0396.2007.00760.x via crossref
- doi:10.1016/s0232-4393(86)80019-1 via crossref
- doi:10.4103/0974-8490.69108 via crossref
- doi:10.1016/s0944-7113(97)80055-4 via crossref
- doi:10.1038/s41598-020-59121-0 via crossref
- doi:10.3390/molecules21010038 via crossref
- doi:10.3109/09637480903193049 via crossref
- doi:10.4314/tjpr.v7i4.14700 via crossref
- doi:10.1111/1750-3841.12462 via crossref
- doi:10.1016/0168-1605(91)90051-p via crossref
- doi:10.3390/coatings11121438 via crossref
- doi:10.1111/lam.12838 via crossref
- doi:10.1016/j.rvsc.2021.03.001 via crossref
- doi:10.2217/fmb-2019-0320 via crossref
- doi:10.1007/s13668-018-0228-z via crossref
- doi:10.3390/antibiotics8030138 via crossref
- doi:10.1093/advances/nmy037 via crossref
- doi:10.1080/10408398.2015.1072083 via crossref
- doi:10.1016/s2222-1808(14)60572-7 via crossref
- doi:10.3390/ijms23137179 via crossref
- doi:10.3390/antibiotics10111306 via crossref
- doi:10.1016/j.jfca.2006.08.004 via crossref
- doi:10.1111/jfs.12679 via crossref
- doi:10.1128/spectrum.00422-22 via crossref
- doi:10.1038/nprot.2007.521 via crossref
- doi:10.1038/nrmicro.2018.17 via crossref
- doi:10.4141/cjps10086 via crossref
- doi:10.1016/j.colsurfb.2011.02.023 via crossref
Source provenance
- crossref
- last seen: 2026-07-27T06:55:27.023760+00:00
- europepmc
- last seen: 2026-05-19T01:45:01.086888+00:00
- unpaywall
- last seen: 2026-05-22T02:00:06.705733+00:00
License: CC-BY-NC-ND-4.0